What caused IGPH.SW stock to drop 25% pre-market?

The pre-market drop to CHF 0.0015 was driven by heavy selling and thin liquidity. Volume spiked to 2,033,000 versus average 193,941. With a tiny market cap and weak fundamentals, small orders can move the price sharply.

What is Meyka AI’s view on IGPH.SW stock?

Meyka AI rates IGPH.SW **58.59** (Grade C+, HOLD). The grade weighs benchmark and sector comparisons, growth, key metrics and consensus. It flags liquidity and cashflow risk as primary concerns.

Are there realistic price targets for IGPH.SW stock?

Scenario targets: bear CHF 0.0005 (down 66.67%), recovery CHF 0.0050 (up 233.33%), extreme downside CHF 0.0001 (down 93.33%). Use these only as scenario guidance, not investment advice.

How should traders approach IGPH.SW in the pre-market?

Use small position sizes, limit orders and tight stop-losses. Expect wide spreads and fast moves. Focus on event triggers and monitor order book depth before committing size.

CH Stocks

IGPH.SW IGEA Pharma (SIX) down 25% pre-market to CHF 0.0015 03 Feb 2026: liquidity risk

ByDanny Kontos February 3, 2026

IGPH.SW stock opened the pre-market session on 03 Feb 2026 at CHF 0.0015, down 25.00% from the prior close. Trading is heavy with 2,033,000 shares reported so far, roughly ten times average volume, flagging it as one of the most active names on the SIX pre-market list. Investors should note the company’s tiny market cap (around CHF 505,545.00), negative EPS (-0.03) and weak liquidity metrics. This article breaks down price action, fundamentals, Meyka AI grade and short-term trade outlook for IGEA Pharma N.V. (IGPH.SW) on the SIX in Switzerland.